PreveCeutical Medical Inc. Announces Launch of New Website for BioGene Therapeutics Inc., Expanding Its Digital Presence to Enhance Accessibility and Awareness of Innovative Therapies
PreveCeutical Medical Inc. (PRVCF) has announced the launch of a new website for its majority-owned subsidiary, BioGene Therapeutics Inc., a Texas-based life sciences company. The website aims to showcase BioGene's research and development initiatives, particularly focusing on metabolic health and gene-based treatments.
Through its wholly-owned subsidiary BioGene Australia, the company is conducting research on GLP-1 receptor agonists and advanced diabetes treatments, including gene therapies targeting the global diabetes and obesity crisis. The website launch is part of BioGene's growth strategy to enhance stakeholder communication and industry engagement.
PreveCeutical Medical Inc. (PRVCF) ha annunciato il lancio di un nuovo sito web per la sua controllata di maggioranza, BioGene Therapeutics Inc., un'azienda texana nel settore delle scienze della vita. Il sito è progettato per mettere in evidenza le iniziative di ricerca e sviluppo di BioGene, con particolare attenzione alla salute metabolica e ai trattamenti basati sulla terapia genica.
Attraverso la sua controllata interamente posseduta BioGene Australia, l'azienda conduce ricerche su agonisti del recettore GLP-1 e trattamenti avanzati per il diabete, comprese terapie geniche mirate a contrastare la crisi globale di diabete e obesità. Il lancio del sito web fa parte della strategia di crescita di BioGene per migliorare la comunicazione con gli stakeholder e l'interazione con il settore.
PreveCeutical Medical Inc. (PRVCF) ha anunciado el lanzamiento de un nuevo sitio web para su subsidiaria mayoritaria, BioGene Therapeutics Inc., una empresa de ciencias de la vida con sede en Texas. El sitio web tiene como objetivo mostrar las iniciativas de investigación y desarrollo de BioGene, con un enfoque especial en la salud metabólica y los tratamientos basados en terapias génicas.
A través de su subsidiaria de propiedad total BioGene Australia, la compañía está investigando agonistas del receptor GLP-1 y tratamientos avanzados para la diabetes, incluyendo terapias génicas dirigidas a la crisis global de diabetes y obesidad. El lanzamiento del sitio web forma parte de la estrategia de crecimiento de BioGene para mejorar la comunicación con sus partes interesadas y la participación en la industria.
PreveCeutical Medical Inc. (PRVCF)는 텍사스에 기반을 둔 생명과학 회사인 자회사 BioGene Therapeutics Inc.의 새로운 웹사이트 출범을 발표했습니다. 이 웹사이트는 BioGene의 연구개발 활동을 소개하며, 특히 대사 건강과 유전자 기반 치료법에 중점을 두고 있습니다.
완전 자회사인 BioGene Australia를 통해 회사는 GLP-1 수용체 작용제 및 첨단 당뇨병 치료법, 특히 전 세계 당뇨병 및 비만 문제를 겨냥한 유전자 치료 연구를 진행 중입니다. 웹사이트 출범은 이해관계자 소통과 산업 참여를 강화하기 위한 BioGene의 성장 전략의 일환입니다.
PreveCeutical Medical Inc. (PRVCF) a annoncé le lancement d’un nouveau site web pour sa filiale majoritaire, BioGene Therapeutics Inc., une entreprise texane spécialisée dans les sciences de la vie. Ce site a pour objectif de mettre en avant les initiatives de recherche et développement de BioGene, en se concentrant particulièrement sur la santé métabolique et les traitements basés sur la thérapie génique.
À travers sa filiale détenue à 100 % BioGene Australia, la société mène des recherches sur les agonistes des récepteurs GLP-1 et les traitements avancés du diabète, incluant des thérapies géniques ciblant la crise mondiale du diabète et de l’obésité. Le lancement du site web s’inscrit dans la stratégie de croissance de BioGene visant à améliorer la communication avec les parties prenantes et l’engagement dans l’industrie.
PreveCeutical Medical Inc. (PRVCF) hat den Start einer neuen Webseite für seine mehrheitlich gehaltene Tochtergesellschaft BioGene Therapeutics Inc., ein Life-Sciences-Unternehmen mit Sitz in Texas, bekannt gegeben. Die Webseite soll die Forschungs- und Entwicklungsinitiativen von BioGene präsentieren, mit besonderem Fokus auf Stoffwechselgesundheit und genbasierte Behandlungen.
Über seine hundertprozentige Tochtergesellschaft BioGene Australia betreibt das Unternehmen Forschung zu GLP-1-Rezeptoragonisten und fortschrittlichen Diabetesbehandlungen, einschließlich Gentherapien zur Bekämpfung der globalen Diabetes- und Adipositas-Krise. Der Start der Webseite ist Teil der Wachstumsstrategie von BioGene, um die Kommunikation mit Stakeholdern und die Branchenbeteiligung zu verbessern.
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is thrilled to announce that BioGene Therapeutics Inc. ("BioGene"), a majority-owned subsidiary of the Company, has officially launched its new website. BioGene is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments.
The newly launched website is a pivotal component of BioGene's growth strategy, designed to provide comprehensive information about the company's cutting-edge research and development initiatives. It serves as a resource for stakeholders, potential partners, and the scientific community to stay informed about BioGene's advancements and contributions to the field of life sciences.
BioGene is currently engaged in groundbreaking research into GLP-1 receptor agonists and advanced diabetes treatments through a wholly-owned subsidiary, BioGene Australia. This includes exploring gene therapies designed to address the growing global diabetes and obesity crisis, positioning BioGene at the forefront of developing next-generation therapeutic solutions.
PreveCeutical and BioGene are dedicated to making significant strides in medical research and delivering innovative treatments that improve health outcomes globally. The launch of BioGene's new website marks a significant milestone in enhancing the company's digital presence and fostering greater engagement with the broader scientific and medical communities.
About BioGene Therapeutics Inc.
BioGene, a Texas-based life sciences company, focuses on metabolic health and gene therapies. Its wholly-owned subsidiary, BioGene Australia, benefits from Australia's R&D tax cashback incentive, helping in research and development. The subsidiary focuses on GLP-1 receptor agonists and advanced diabetes treatments to address global diabetes and obesity issues. For more information about BioGene, please visit www.biogenetherapeutics.com.
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations
ir@preveceutical.com
Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252072
FAQ
What is the purpose of BioGene Therapeutics' new website launched by PRVCF?
What type of research is BioGene Therapeutics currently conducting?
Who owns BioGene Therapeutics and where is it based?
What is PreveCeutical Medical's (PRVCF) main business focus?
